首页 | 本学科首页   官方微博 | 高级检索  
     

湖南省细菌耐药监测网2012—2021年尿标本分离细菌耐药监测报告
引用本文:税剑,陈丽华,李晨,李艳明,刘君,宁兴旺,邬靖敏,杨怀德,袁红霞,郑铭,任南,吴安华,黄勋,付陈超,石国民. 湖南省细菌耐药监测网2012—2021年尿标本分离细菌耐药监测报告[J]. 中国感染控制杂志, 2024, 23(4): 448-457
作者姓名:税剑  陈丽华  李晨  李艳明  刘君  宁兴旺  邬靖敏  杨怀德  袁红霞  郑铭  任南  吴安华  黄勋  付陈超  石国民
作者单位:1. 长沙市中心医院检验科;2. 中南大学湘雅三医院检验科;3. 浏阳市中医医院检验科;4. 中南大学湘雅医院检验科;5. 湘潭市中心医院检验科;6. 湖南中医药大学第一附属医院医学检验与病理中心;7. 长沙市第一医院检验科;8. 张家界市人民医院检验科;9. 郴州市第一人民医院检验医学中心;10. 中南大学湘雅医院医院感染控制中心;12. 国家老年疾病临床医学研究中心(湘雅医院);13. 湖南省医院感染管理质量控制中心
基金项目:湖南省自然科学基金项目(2021JJ40624);
摘    要:目的 了解湖南省临床尿标本细菌分布及耐药情况,为尿路感染患者的抗感染治疗提供科学依据。方法 按照全国细菌耐药监测网技术方案要求开展细菌耐药监测工作,参考美国临床实验室标准化协会标准判断药敏试验结果,应用WHONET 5.6软件分析2012—2021年湖南省细菌耐药监测网成员单位上报的尿标本分离细菌的菌株资料及耐药性数据。结果 2012—2021年尿标本检出细菌379 330株,其中革兰阴性菌占75.3%(72.4%~76.0%),革兰阳性菌占24.7%(24.0%~27.6%)。革兰阴性菌中居前5位的细菌分别为大肠埃希菌(48.3%)、肺炎克雷伯菌(8.4%)、奇异变形杆菌(3.3%)、铜绿假单胞菌(3.0%)、阴沟肠杆菌(1.6%)。革兰阳性菌中居前5位的细菌分别为屎肠球菌(8.1%)、粪肠球菌(6.6%)、表皮葡萄球菌(1.9%)、金黄色葡萄球菌(1.9%)、溶血葡萄球菌(1.4%)。不同性别及不同年龄段患者尿标本检出细菌构成不同,居首位的大肠埃希菌在男性、女性中分别占34.8%、57.2%,在成人和儿童中分别占49.0%、34.4%。大肠埃希菌对碳青霉烯类抗生素、阿米卡星、替加环...

关 键 词:尿路感染  抗菌药物  耐药性  监测  湖南省细菌耐药监测网
收稿时间:2024-01-22

Antimicrobial resistance of bacteria isolated from urine specimens: surveillance report from Hunan Province Antimicrobial Resistance Surveillance System, 2012-2021
Jian SHUI,Li-hua CHEN,Chen LI,Yan-ming LI,Jun LIU,Xing-wang NING,Jing-min WU,Huai-de YANG,Hong-xia YUAN,Ming ZHENG,Nan REN,An-hua WU,Xun HUANG,Chen-chao FU,Guo-min SHI. Antimicrobial resistance of bacteria isolated from urine specimens: surveillance report from Hunan Province Antimicrobial Resistance Surveillance System, 2012-2021[J]. Chinese Journal of Infection Control, 2024, 23(4): 448-457
Authors:Jian SHUI  Li-hua CHEN  Chen LI  Yan-ming LI  Jun LIU  Xing-wang NING  Jing-min WU  Huai-de YANG  Hong-xia YUAN  Ming ZHENG  Nan REN  An-hua WU  Xun HUANG  Chen-chao FU  Guo-min SHI
Affiliation:1.Department of Laboratory Medicine, Changsha Central Hospital, Changsha 410004, China;2.Department of Laboratory Medicine, The Third Xiangya Hospital of Central South University, Changsha 410013, China;3.Department of Laboratory Medicine, Liuyang Traditional Chinese Medicine Hospital, Liuyang 410300, China;4.Department of Laboratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China;5.Department of Laboratory Medicine, Xiangtan Central Hospital, Xiangtan 411100, China;6.Medical Laboratory and Patho-logy Center, The First Hospital of Hunan University of Chinese Medicine, Changsha 410011, China;7.Department of Laboratory Medicine, The First Hospital of Changsha, Changsha 410005, China;8.Department of Laboratory Medicine, Zhangjiajie People''s Hospital, Zhangjiajie 427000, China;9.Center for Laboratory Medicine, The First People''s Hospital of Chenzhou, Chenzhou 423000, China;10.Center for Healthcare-associated Infection Control, Xiangya Hospital, Central South University, Changsha 410008, China;11.Hunan Province Antimicrobial Resistance Surveillance System Office, Changsha 410008, China;12.National Clinical Research Center for Geriatric Disorders [Xiangya Hospital], Changsha 410008, China;13.Hunan Provincial Healthcare-associated Infection Management Quality Control Center, Changsha 410008, China
Abstract:Objective To understand the distribution and antimicrobial resistance of bacteria from clinical urine specimens in Hunan Province, and provide scientific basis for anti-infection treatment of patients with urinary tract infection (UTI). Methods Bacterial resistance surveillance was carried out according to the technical scheme requirements of China Antimicrobial Resistance Surveillance System, antimicrobial susceptibility testing results were judged based on standard of American Clinical and Laboratory Standards Institute, data about strains and antimicrobial resistance of bacteria from urine specimens reported by member units of Hunan Province Antimicrobial Resistance Surveillance System in 2012-2021 were analyzed with WHONET 5.6 software. Results A total of 379 330 strains of bacteria were isolated from urine specimens in 2012-2021, Gram-negative and Gram-positive bacteria accounted for 75.3% (72.4%-76.0%) and 24.7% (24.0%-27.6%), respectively. The top 5 Gram-negative bacteria were Escherichia coli (48.3%), Klebsiella pneumoniae (8.4%), Proteus mirabilis (3.3%), Pseudomonas aeruginosa (3.0%) and Enterobacter cloacae (1.6%). The top 5 Gram-positive bacteria were Enterococcus faecium (8.1%), Enterococcus faecalis (6.6%), Staphylococcus epidermidis (1.9%), Staphylococcus aureus (1.9%) and Staphylococcus haemolyticus (1.4%). The constituent of bacteria isolated from urine specimens of patients in different gender and age groups were different. Escherichia coli ranked first, accounting for 34.8% and 57.2% in males and females, respectively, as well as 49.0% and 34.4% in adults and children, respectively. Escherichia coli maintained high susceptibility to carbapenems, amikacin, tigecycline, cefoperazone/sulbactam and furantoin, with resistance rate < 10%, while resistance to cefazolin, cefuroxime, ceftriaxone, cefotaxime and quinolones were relatively higher, with resistance rate >48%; resistance rates to ceftazidime, ceftriaxone, cefotaxime, cefepime and aztreonam presented decreased trend (all P < 0.001). Klebsiella pneumoniae maintained higher susceptibility to carbapenems, amikacin and tigecycline, with resistance rate < 11%, resistance rate to quinolones was much lower than that of Escherichia coli. Enterococcus faecium and Enterococcus faecalis maintained high susceptibility to vancomycin, teicoplanin and linezolid, with resistance rates < 5%; resistance rate of Enterococcus faecalis to ampicillin and furantoin was < 15%. Except for linezolid and minocycline, resistance rates of Enterococcus faecium to the other tested antimicrobial agents were all higher than Enterococcus faecalis. No Staphylococcus aureus was found to be resistant to vancomycin, linezolid and teicoplanin. Conclusion Escherichia coli is the main bacteria isolated from urine specimens from various member units of Hunan Province Antimicrobial Resistance Surveillance System. In early empirical treatment, clinical antimicrobial should be targetedly used as early as possible based on bacterial identification and antimicrobial susceptibility testing results, so as to improve treatment effectiveness and slow down the emergence of antimicrobial resistance.
Keywords:urinary tract infection  antimicrobial agent  antimicrobial resistance  surveillance  Hunan Province Antimicrobial Resistance Surveillance System
点击此处可从《中国感染控制杂志》浏览原始摘要信息
点击此处可从《中国感染控制杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号